The presented results could also be relevant in order to choose the best chemotherapeutic option for pediatric gliomas treatment, however, it is necessary to perform more studies to know if CYP2B6 expression could be used as a CPA-based chemotherapy response marker. The gene discussed is CYP2B6; the disease is central nervous system cancer.